Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
BCR-ABL1-negative myeloproliferative disorders and chronic myeloid leukaemia are haematologic malignancies characterised by single and mutually exclusive genetic alterations.
|
30965317 |
2019 |
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Chronic myeloid leukemia (CML) is a myeloproliferative disease caused by the constitutive tyrosine kinase (TK) activity of the BCR-ABL1 fusion protein.
|
31122263 |
2019 |
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
This study aimed to elucidate patterns of disease transformation to secondary myelofibrosis (SMF) or secondary acute myeloid leukemia (SAML) and the development of second primary malignancies in South Korean patients with BCR-ABL1-negative myeloproliferative neoplasms (MPNs).
|
31765478 |
2019 |
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm the hallmark of which, the breakpoint cluster region-Abelson (BCR-ABL) oncogene, has been the target of tyrosine kinase inhibitors (TKIs), which have significantly improved the survival of patients with CML.
|
31102734 |
2019 |
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
Chronic neutrophilic leukemia (CNL) is a BCR-ABL1-negative myeloproliferative neoplasm with notably dismal survival.
|
30581159 |
2019 |
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
The hallmark of <i>BCR-ABL1</i>-negative myeloproliferative neoplasms (MPNs) is the presence of a driver mutation in <i>JAK2, CALR</i>, or <i>MPL</i> gene.
|
31106152 |
2019 |
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Starting from this observation, we extended our study to a panel of human leukemic cells carrying genetic lesions distinctive of different types of leukemias and myeloproliferative disorders (the BCR-ABL1 translocation and the JAK2V617F amino acid substitution) to dissect the cellular events induced by SOX6.
|
30833651 |
2019 |
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The Janus kinase 2 (<i>JAK2</i>) V617F mutation is common in patients with breakpoint cluster region-Abelson1 (<i>BCR-ABL1</i>)-negative myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and primary myelofibrosis, but is rarely detected in <i>BCR-ABL1-</i>positive chronic myeloid leukemia (CML) patients.
|
31123683 |
2019 |
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
Renal complications related to BCR-ABL1-negative myeloproliferative neoplasms (MPNs) have not been examined fully in Asian populations.
|
28298076 |
2018 |
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Thromboembolic events are the main cause of mortality in BCR-ABL1-negative myeloproliferative neoplasms (MPNs) but their underlying mechanisms are largely unrecognized.
|
30103245 |
2018 |
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
Although BCR-ABL1-negative myeloproliferative neoplasms (MPN) are chronic, clonal hematopoietic stem cell (HSC) disorders marked by proliferation of one or more myeloid lineages, a substantial proportion of patients transform to acute myeloid leukemia.
|
30353413 |
2018 |
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Angiogenesis and JAK2 V617F mutation are common in BCR-ABL1 negative myeloproliferative neoplasms (MPNs).
|
28554272 |
2018 |
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
BCR/ABL1-negative myeloproliferative neoplasms (MPNs) are characterized by recurrent mutations in JAK2, CALR, and MPL, each of which has been reported to alter JAK/STAT signaling pathways.
|
27258562 |
2018 |
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Myeloproliferative neoplasms (MPNs) are classically divided into BCR RhoGEF and GTPase activating protein (BCR)-ABL proto‑oncogene 1 non‑receptor tyrosine kinase (ABL) positive chronic myeloid leukemia (CML) and BCR‑ABL negative MPNs, including essential thrombocythemia (ET).
|
29845291 |
2018 |
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy.
|
30084669 |
2018 |
Myeloproliferative disease
|
0.500 |
AlteredExpression
|
group |
BEFREE |
This event results in the expression of the BCR-ABL1 fusion gene, which codes for a constitutively active tyrosine kinase that is responsible for the transformation of a HSC into a CML stem cell, which then gives rise to a clonal myeloproliferative disease.
|
29500381 |
2018 |
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
|
28990497 |
2018 |
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
Primary myelofibrosis (PMF) is one of the classic BCR-ABL1 negative myeloproliferative neoplasms (MPN).
|
29256926 |
2018 |
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
This study aimed to determine GATA1 expression levels to better characterize subgroups in BCR/ABL1-negative myeloproliferative neoplasms (MPNs).
|
29611379 |
2018 |
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
To characterize the clinicopathologic features of myeloproliferative neoplasms with concomitant BCR-ABL1 and JAK2 V617F, and define the frequency of co-occurrence, we conducted a retrospective multi-institutional study.
|
29327708 |
2018 |
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
Alterations in the bone marrow niche induced by abnormal production of cytokines and other soluble factors have been associated with disease progression in classical BCR-ABL1 negative myeloproliferative neoplasms (MPN).
|
29975001 |
2018 |
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
Increased angiogenesis in BCR-ABL1 negative myeloproliferative neoplasms (MPNs) has been recognized, but its connection with clinical and molecular markers needs to be defined.
|
27924369 |
2017 |
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
BCR-ABL1-negative myeloproliferative neoplasms (MPNs) are clonal stem cell disorders defined by proliferation of one or more myeloid lineages, and carry an increased risk of vascular events and progression to myelofibrosis and leukemia.
|
28543980 |
2017 |
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
Classical BCR-ABL1-negative myeloproliferative neoplasms (MPNs) including polycythemia vera, essential thrombocythemia (ET), and primary myelofibrosis frequently harbor JAK2, MPL, and CALR somatic mutations.
|
28406068 |
2017 |
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
Chronic myeloid leukemia (CML) is caused by the acquisition of the tyrosine kinase BCR-ABL1 in a hemopoietic stem cell, transforming it into a leukemic stem cell (LSC) that self-renews, proliferates, and differentiates to give rise to a myeloproliferative disease.
|
28159740 |
2017 |